← Leaderboards
Thomas R Kozel
La Biomed Res Inst/ Harbor Ucla Med Ctr
$22,208,837
Attributed
$25,318,141
Total exposure
18
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–23$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$25,318,141 · 18
By mechanism
R01$12,740,439 · 5
U01$3,295,908 · 1
R44$2,529,379 · 2
R43$1,605,652 · 3
R37$1,542,080 · 1
R41$1,200,000 · 2
Top collaborators
- Amanda Burnham-Marusich12 shared
- David P Aucoin5 shared
- Sean Bauman1 shared
- Beverly Crider1 shared
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionImmunoassayDiagnosisBasePolysaccharidesMonoclonal AntibodiesAntigensEarly DiagnosisDiagnosticDetectionPrototypeRapid DiagnosisAntibodiesSamplingLateralSerumSpecificityPerformanceSuccessDiagnostic TestsAnimal ModelMannansBloodEvaluation
Grant awards (62)
Multiplexed rapid immunoassay for invasive fungal disease$669,571
R01 · FY2023 · AI · contact PI
Multiplexed rapid immunoassay for invasive fungal disease$653,851
R01 · FY2022 · AI · contact PI
Multiplexed rapid immunoassay for invasive fungal disease$681,541
R01 · FY2021 · AI · contact PI
Lateral flow immunoassay for rapid diagnosis of tinea capitis and onychomycosis$893,413
R44 · FY2020 · EB
Multiplexed rapid immunoassay for invasive fungal disease$702,605
R01 · FY2020 · AI · contact PI
Immunoassay for early diagnosis of mucormycosis$298,013
R43 · FY2020 · AI
Lateral flow immunoassay for rapid diagnosis of tinea capitis and onychomycosis$588,922
R44 · FY2019 · EB
Immunoassay for early diagnosis of mucormycosis$297,133
R43 · FY2019 · AI
Point-of-care immunoassay for early diagnosis of pertussis$289,172
R44 · FY2018 · AI
Point-of-care immunoassay for early diagnosis of pertussis$351,332
R44 · FY2017 · AI
Point of care immunoassay for rapid diagnosis of tinea capitis$189,220
R43 · FY2017 · EB
Point-of-care immunoassay for early diagnosis of pertussis$406,540
R44 · FY2016 · AI
Point of care immunoassay for rapid diagnosis of tinea capitis$199,920
R43 · FY2016 · EB
Point of care immunoassay for rapid diagnosis of tinea capitis$31,500
R43 · FY2016 · EB
Immunoassay for capsular antigen for rapid diagnosis of anthrax$498,019
R01 · FY2015 · AI · contact PI
Point-of-care immunoassay for early diagnosis of pertussis$297,775
R43 · FY2015 · AI
Immunoassay for capsular antigen for rapid diagnosis of anthrax$893,748
R01 · FY2014 · AI · contact PI
Target discovery and immunoassay for diagnosis of invasive aspergillosis$336,893
R33 · FY2014 · AI · contact PI
Immunoassay for diagnosis of invasive fungal disease$300,000
R41 · FY2014 · AI
Biomarker discovery for immunodiagnosis of invasive candidiasis$300,000
R41 · FY2014 · AI · contact PI
Point-of-care immunoassay for early diagnosis of pertussis$292,091
R43 · FY2014 · AI
Immunoassay for capsular antigen for rapid diagnosis of anthrax$638,260
R01 · FY2013 · AI · contact PI
Target discovery and immunoassay for diagnosis of invasive aspergillosis$361,662
R33 · FY2013 · AI · contact PI
Immunoassay for diagnosis of invasive fungal disease$300,000
R41 · FY2013 · AI
Biomarker discovery for immunodiagnosis of invasive candidiasis$300,000
R41 · FY2013 · AI · contact PI
Immunoassay for capsular antigen for rapid diagnosis of anthrax$620,422
R01 · FY2012 · AI · contact PI
B. anthracis: passive immunization with anticapsular mAb$541,664
R01 · FY2012 · AI · contact PI
Target discovery and immunoassay for diagnosis of invasive aspergillosis$404,853
R33 · FY2012 · AI · contact PI
Immunoassay for capsular antigen for rapid diagnosis of anthrax$718,102
R01 · FY2011 · AI · contact PI
B. anthracis: passive immunization with anticapsular mAb$557,160
R01 · FY2011 · AI · contact PI
Target discovery and immunoassay for diagnosis of invasive aspergillosis$189,820
R21 · FY2011 · AI · contact PI
B. anthracis: passive immunization with anticapsular mAb$526,732
R01 · FY2010 · AI · contact PI
Antigenemia immunoassay for point of care dianostic melioidosis$278,217
U54 · FY2010 · AI · contact PI
Target discovery and immunoassay for diagnosis of invasive aspergillosis$190,350
R21 · FY2010 · AI · contact PI
PGA antigenemia for early diagnosis of anthrax$833,887
U01 · FY2009 · AI · contact PI
B. anthracis: passive immunization with anticapsular mAb$526,695
R01 · FY2009 · AI · contact PI
Cryptococcal polysaccharide-phagocytosis inhibition$399,185
R01 · FY2009 · AI · contact PI
Antigenemia immunoassay for point of care dianostic melioidosis$279,653
U54 · FY2009 · AI · contact PI
PGA antigenemia for early diagnosis of anthrax$822,013
U01 · FY2008 · AI · contact PI
Cryptococcal polysaccharide-phagocytosis inhibition$387,559
R01 · FY2008 · AI · contact PI
PGA antigenemia for early diagnosis of anthrax$543,723
U01 · FY2007 · AI · contact PI
Cryptococcal polysaccharide-phagocytosis inhibition$383,557
R01 · FY2007 · AI · contact PI
PGA antigenemia for early diagnosis of anthrax$544,085
U01 · FY2006 · AI · contact PI
B. anthracis:passive immunization with anticapsular mAb$469,832
R01 · FY2006 · AI · contact PI
Cryptococcal polysaccharide-phagocytosis inhibition$383,508
R01 · FY2006 · AI · contact PI
PGA antigenemia for early diagnosis of anthrax$552,200
U01 · FY2005 · AI
B. anthracis:passive immunization with anticapsular mAb$447,683
R01 · FY2005 · AI
Cryptococcal polysaccharide-phagocytosis inhibition$381,298
R01 · FY2005 · AI
B. anthracis:passive immunization with anticapsular mAb$445,894
R01 · FY2004 · AI
CRYPTOCOCCAL POLYSACCHARIDE--PHAGOCYTOSIS INHIBITION$326,913
R37 · FY2004 · AI
REGULATION OF COMPLEMENT ACTIVATION BY CANDIDA ALBICANS$257,267
R01 · FY2004 · AI
CRYPTOCOCCAL POLYSACCHARIDE--PHAGOCYTOSIS INHIBITION$317,391
R37 · FY2003 · AI
REGULATION OF COMPLEMENT ACTIVATION BY CANDIDA ALBICANS$249,773
R01 · FY2003 · AI
CRYPTOCOCCAL POLYSACCHARIDE--PHAGOCYTOSIS INHIBITION$308,147
R37 · FY2002 · AI
REGULATION OF COMPLEMENT ACTIVATION BY CANDIDA ALBICANS$242,499
R01 · FY2002 · AI
BIOLOGICAL ACTIVITIES OF NATURAL ANTI-CANDIDA ANTIBODIES$196,218
P01 · FY2002 · AI
CRYPTOCOCCAL POLYSACCHARIDE--PHAGOCYTOSIS INHIBITION$299,172
R37 · FY2001 · AI
REGULATION OF COMPLEMENT ACTIVATION BY CANDIDA ALBICANS$235,436
R01 · FY2001 · AI
BIOLOGICAL ACTIVITIES OF NATURAL ANTI-CANDIDA ANTIBODIES$0
P01 · FY2001 · AI
CRYPTOCOCCAL POLYSACCHARIDE--PHAGOCYTOSIS INHIBITION$290,457
R37 · FY2000 · AI
REGULATION OF COMPLEMENT ACTIVATION BY CANDIDA ALBICANS$228,578
R01 · FY2000 · AI
BIOLOGICAL ACTIVITIES OF NATURAL ANTI-CANDIDA ANTIBODIES$167,017
P01 · FY2000 · AI